154499-13-5

Basic information

• Product Name: (+)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester
• Synonyms: (+)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester;(2R)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester;(R)-N-Benzyloxycarbonyl-2-piperidinemethanol;(R)-1-Cbz-2-(hydroxyMethyl)piperidine
• CAS NO: 154499-13-5
• Molecular Formula: C₁₄H₁₉NO₃
• Molecular Weight: 249.31
• Product Categories: Chiral Reagents;Heterocycles;Chiral Reagents, Heterocycles
• Mol File: 154499-13-5.mol

Chemical Properties

• Boiling Point: 396.374°C at 760 mmHg
• Flash Point: 193.52°C
• Appearance: /
• Density: 1.163g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.55
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (+)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester(154499-13-5)
• EPA Substance Registry System: (+)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester(154499-13-5)

Safety Data

• Hazardous Substances Data: 154499-13-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(+)-2-(Hydroxymethyl)-1-piperidinecarboxylic Acid Phenylmethyl Ester is used as an intermediate for the preparation of 1-hydroxyalkyl-3-phenylthioureas. These compounds are known as HDLand Apo A-I-elevating agents, which are beneficial in the treatment of cardiovascular diseases by increasing the levels of high-density lipoprotein (HDL) and apolipoprotein A-I in the body.

InChI:InChI=1/C14H19NO3/c16-10-13-8-4-5-9-15(13)14(17)18-11-12-6-2-1-3-7-12/h1-3,6-7,13,16H,4-5,8-11H2/t13-/m1/s1

Upstream product

• 28697-07-6 (R)-1-((benzyloxy)carbonyl)piperidine-2-carboxylic acid 
• 123-20-6 vinyl n-butyrate 
• 105706-75-0 1-benzyloxycarbonyl-2-hydroxymethylpiperidine 
• 60369-19-9 (2R)-N-(benzyloxycarbonyl)-2-(methoxycarbonyl)piperidine 
• 1723-00-8 (R)-(+)-pipecolic acid 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1192122-36-3 [(2R)-1-[(benzyloxy)carbonyl]piperidin-2-yl]methyl 4-methylpiperazine-1-carboxylate 
• 1389312-78-0 C₁₇H₂₃NO₆ 
• 1389312-79-1 C₁₇H₂₃NO₆ 
• 160096-51-5 (R)-2-((1R,2S)-2-Ethoxycarbonyl-1,2-dihydroxy-ethyl)-piperidine-1-carboxylic acid benzyl ester 
• 160169-47-1 (R)-2-((E)-2-Ethoxycarbonyl-vinyl)-piperidine-1-carboxylic acid benzyl ester 
• 160169-49-3 (1R,2S,8aR)-1,2-dihydroxy-hexahydroindolizin-3(5H)-one 
• 125279-72-3 (1R,2R,8aR)-lentiginosine 
• 539823-50-2 (R,E)-methyl 3-[1-(2-iodobenzoyl)piperidin-2-yl]acrylate 
• 539823-49-9 (R)-2-hydroxymethyl-1-(2-iodobenzoyl)piperidine 
• 3197-44-2 (2R)-piperidin-2-ylmethanol 
• 1068012-41-8 (R)-N-(benzyloxycarbonyl)-2-formylpiperidine 

Relevant articles and documents

3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

Chemoenzymatic synthesis, structural study and biological activity of novel indolizidine and quinolizidine iminocyclitols

The synthesis, conformational study and inhibitory properties of diverse indolizidine and quinolizidine iminocyclitols are described. The compounds were chemo-enzymatically synthesized by two-step aldol addition and reductive amination reactions. The aldol addition of dihydroxyacetone phosphate (DHAP) to N-Cbz-piperidine carbaldehyde derivatives catalyzed by l-rhamnulose 1-phosphate aldolase from Escherichia coli provides the key intermediates. The stereochemical outcome of both aldol addition and reductive amination depended upon the structure of the starting material and intermediates. The combination of both reactions furnished five indolizidine and six quinolizidine type iminocyclitols. A structural analysis by NMR and in silico density functional theory (DFT) calculations allowed us to determine the population of stereoisomers with the trans or cis ring fusion, as a consequence of the inversion of configuration of the bridgehead nitrogen. The trans fusion was by far the most stable, but for certain stereochemical configurations of the 3-hydroxymethyl and hydroxyl substituents both trans and cis fusion stereoisomers coexisted in different proportions. Some of the polyhydroxylated indolizidines and quinolizidines were shown to be moderate to good inhibitors against α-l-rhamnosidase from Penicillium decumbens. Indolizidines were found to be moderate inhibitors of the rat intestinal sucrase and of the exoglucosidase amyloglucosidase from Aspergillus niger. In spite of their activity against α-l-rhamnosidase, all the compounds were ineffective to inhibit the growth of the Mycobacterium tuberculosis, the causative agent of tuberculosis. The Royal Society of Chemistry 2012.

QUINAZOLINE DERIVATIVES

The invention provided a compound of formula (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also

POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY

The present invention is to provide a novel compound (I), having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. Compound (I) wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.

1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents

A series of 1-hydroxyalkyl-3-phenylthiourea analogs were prepared and evaluated as HDL-and Apo A-I-elevating agents. Derivatives 5h, 7j, 7n, and 7o were found to be as effective or superior to gemfibrozil (1).

Synthesis of heterocyclic γ-amino-α,β-unsaturated acid derivatives and peptide-heterocycle hybrids

The syntheses of the γ-amino-α,β-unsaturated esters [(R)-4, (S)-5, and (±)-6] are reported. The methodology for the preparation of these triannular heterocycles involves two synthetic sequences from N-substituted amino alcohols: a 'one-pot' sequential Swe

Stereoselective synthesis of (+)-and (-)-lentiginosine

Simple routes to (1R,2R,8aR)- and (1S,2S,8aS)-lentiginosine have been described, based on Sharpless asymmetric dihydroxylation, starting from (R)- and (S)-pipecolinic acids.